[SCHEDULE 13G] Purple Biotech Ltd. American SEC Filing

Rhea-AI Filing Summary

Purple Biotech Ltd. received a joint Schedule 13G from Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reporting shared beneficial ownership of 139,632,475 ordinary shares, representing 9.99% of the class as of September 10, 2025. The filing explains those shares include issued shares and shares issuable on exercise of two warrants, but each warrant contains a blocker provision preventing exercise that would increase beneficial ownership above 9.99%. The reporting persons state the holdings were not acquired to change or influence issuer control and filed a joint filing agreement.

Positive

• Transparent disclosure of beneficial ownership at 9.99% by three reporting persons with a joint filing agreement
• Blocker provisions in the warrants explicitly limit exercise that would push beneficial ownership above 9.99%, constraining immediate control shifts

Negative

• Substantial warrant exposure (multiple warrants and large numbers of issuable shares) creates potential future dilution if blocker provisions change
• High shared voting power (139,632,475 shares) signals concentrated influence despite the filing's certification of no intent to change control

Insights

Financial Analyst

TL;DR: A disclosed 9.99% position with large warrant exposure creates potential dilution but is contractually capped by blocker provisions.

The Reporting Persons disclose shared beneficial ownership of 139,632,475 shares (9.99%) including issued shares and warrants. Material to investors is the scale of potential dilution: absent blocker provisions, their combined holdings could represent hundreds of millions of shares. The presence of blocker provisions limits immediate exercise and control shifts, reducing near-term governance risk, but the warrants represent latent dilution that market participants should note when assessing share count dynamics.

Corporate Governance Expert

TL;DR: Joint filing and certification indicate no stated intent to change control, while shared voting power is substantial.

The Schedule 13G is filed jointly and includes certifications that the securities were not acquired to influence control. Despite that, the Reporting Persons report shared voting power of 139,632,475 shares and shared dispositive power of 124,132,475 shares. The blocker provisions on warrants limit conversion-triggered control changes, but the filing highlights significant coordinated influence potential given the large shared voting stake.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Purple Biotech Ltd.

(Name of Issuer)

Ordinary shares, no par value per share

(Title of Class of Securities)

74638P208

(CUSIP Number)

09/04/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74638P208

1

Names of Reporting Persons

Mitchell P. Kopin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 139,632,475.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 124,132,475.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

139,632,475.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 74638P208

1

Names of Reporting Persons

Daniel B. Asher

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 139,632,475.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 124,132,475.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

139,632,475.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 74638P208

1

Names of Reporting Persons

Intracoastal Capital LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 139,632,475.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 124,132,475.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

139,632,475.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Purple Biotech Ltd.
(b)	Address of issuer's principal executive offices: 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)	Citizenship: Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)	Title of class of securities: Ordinary shares, no par value per share
(e)	CUSIP No.: 74638P208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on September 4, 2025 (the "SPA") (as disclosed in the Form 6-K filed by the Issuer with the Securities and Exchange Commission on September 5, 2025), each of the Reporting Persons may have been deemed to have beneficial ownership of 67,268,515 Ordinary Shares, which consisted of (i) 67,000,000 Ordinary Shares to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 268,515 Ordinary Shares issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 1"), and all such Ordinary Shares represent beneficial ownership of approximately 9.99% of the Ordinary Shares, based on (1) 606,090,001 Ordinary Shares outstanding as of August 27, 2025, as reported by the Issuer, plus (2) 67,000,000 Ordinary Shares to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (3) 268,515 Ordinary Shares issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 132,731,485 Ordinary Shares issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Ordinary Shares and (II) 400,000,000 Ordinary Shares issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Ordinary Shares. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 600,000,000 Ordinary Shares. (ii) As of the close of business on September 10, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 139,632,475 Ordinary Shares, which consisted of (i) 61,000,000 Ordinary Shares held by Intracoastal, (ii) 31,000,000 Ordinary Shares issuable upon exercise of Intracoastal Warrant 1 and (iii) 47,632,475 Ordinary Shares issuable upon exercise of Intracoastal Warrant 2, and all such Ordinary Shares represent beneficial ownership of approximately 9.99% of the Ordinary Shares, based on (1) 606,090,001 Ordinary Shares outstanding as of August 27, 2025, as reported by the Issuer, plus (2) 611,000,000 Ordinary Shares issued at the closing of the transaction contemplated by the SPA, (3) 102,000,000 Ordinary Shares issued to Intracoastal upon exercise of Intracoastal Warrant 1, (4) 31,000,000 Ordinary Shares issuable upon exercise of Intracoastal Warrant 1 and (5) 47,632,475 Ordinary Shares issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes 352,367,525 Ordinary Shares issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Ordinary Shares. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 492,000,000 Ordinary Shares.
(b)	Percent of class: 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 139,632,475
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 124,132,475
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mitchell P. Kopin

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin
Date:	09/10/2025

Daniel B. Asher

Signature:	/s/ Daniel B. Asher
Name/Title:	Daniel B. Asher
Date:	09/10/2025

Intracoastal Capital LLC

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin, Manager
Date:	09/10/2025

Exhibit Information

Exhibit 1 - Joint Filing Agreement

FAQ

What stake did Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital report in Purple Biotech (PPBT)?

They reported shared beneficial ownership of 139,632,475 ordinary shares, representing 9.99% of the class as of September 10, 2025.

Do the reported holdings include warrants or other issuable shares in PPBT?

Yes. The amount includes shares issued to Intracoastal and shares issuable upon exercise of two warrants described in the filing, with specific numbers detailed in Item 4.

What are the blocker provisions mentioned in the Schedule 13G for PPBT?

Both warrants contain provisions preventing exercise to the extent that such exercise would cause the holder and its affiliates to beneficially own more than 9.99% of the ordinary shares.

Did the Reporting Persons state an intent to change or influence control of Purple Biotech (PPBT)?

No. The filing includes a certification that, to the best of their knowledge, the securities were not acquired and are not held to change or influence control of the issuer.

How much shared voting and dispositive power do the filers report for PPBT?

They report shared voting power of 139,632,475 shares and shared dispositive power of 124,132,475 shares.

When was the Schedule 13G filed that discloses the PPBT ownership?

The signatures in the filing are dated September 10, 2025, and the referenced triggering event is dated September 4, 2025.